Hims & Hers Health (NYSE:HIMS) Stock Price Down 6% Following Analyst Downgrade

Hims & Hers Health, Inc. (NYSE:HIMS) shares fell 6% on Tuesday after TD Cowen lowered their price target on the stock from $30.00 to $20.00. TD Cowen currently has a hold rating on the stock. Hims & Hers Health traded as low as $18.11 and last traded at $18.1760. 26,490,284 shares were traded during trading, an increase of 3% from the average session volume of 25,699,619 shares. The stock had previously closed at $19.33.

A number of other brokerages have also recently issued reports on HIMS. UBS Group set a $32.00 target price on shares of Hims & Hers Health in a report on Tuesday, November 4th. Wall Street Zen lowered Hims & Hers Health from a “hold” rating to a “sell” rating in a research note on Saturday, November 8th. Evercore initiated coverage on Hims & Hers Health in a research note on Monday, January 12th. They set an “in-line” rating and a $33.00 target price for the company. Leerink Partners raised Hims & Hers Health from a “hold” rating to a “strong-buy” rating in a report on Thursday, December 4th. Finally, Citigroup cut their price target on Hims & Hers Health from $30.00 to $16.50 and set a “sell” rating for the company in a report on Monday. One analyst has rated the stock with a Strong Buy rating, three have assigned a Buy rating, nine have assigned a Hold rating and four have issued a Sell rating to the company. According to data from MarketBeat.com, Hims & Hers Health currently has an average rating of “Hold” and a consensus target price of $39.32.

Insider Activity

In other Hims & Hers Health news, insider Patrick Harrison Carroll sold 10,021 shares of the business’s stock in a transaction on Wednesday, December 17th. The stock was sold at an average price of $36.71, for a total value of $367,870.91. Following the sale, the insider directly owned 169,940 shares in the company, valued at $6,238,497.40. The trade was a 5.57% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, CFO Oluyemi Okupe sold 23,187 shares of the stock in a transaction on Monday, November 17th. The stock was sold at an average price of $36.81, for a total value of $853,513.47. Following the transaction, the chief financial officer owned 70,232 shares of the company’s stock, valued at $2,585,239.92. The trade was a 24.82% decrease in their position. The SEC filing for this sale provides additional information. Over the last ninety days, insiders sold 129,337 shares of company stock worth $4,651,648. 13.71% of the stock is owned by insiders.

Key Stories Impacting Hims & Hers Health

Here are the key news stories impacting Hims & Hers Health this week:

• Positive Sentiment: Company growth: analysts note HIMS is expanding into new specialties and proactive testing, with revenue and subscriber growth that support long‑term addressable market opportunity. HIMS Dips 55.8% in 3 Months: Should You Still Hold the Stock or Sell?
• Neutral Sentiment: Survivability view: some commentators say the company can survive the shakeout but warn investors to expect a significant washout in the stock as regulatory/legal noise plays out. Hims & Hers Health: The Company Will Survive, But Investors Should Expect A ‘Washout’
• Negative Sentiment: Lawsuit from Novo Nordisk: Novo filed a U.S. patent suit alleging HIMS sold a compounded copy of Wegovy, escalating legal risk and potential injunctions or damages exposure. Novo Nordisk opens new front with patent suit over Hims’ Wegovy copies
• Negative Sentiment: FDA enforcement and warning letter: the FDA flagged HIMS over its compounded GLP‑1 pill activity, increasing regulatory scrutiny and the risk of forced product removals. Hims & Hers’ Woes Compound as FDA Hits Company With Warning Letter
• Negative Sentiment: Product withdrawal after threats: HIMS pulled its $49 GLP‑1/“Wegovy‑like” pill following FDA warnings and legal threats, undermining the strategic thesis that the product would be a fast revenue driver. Hims & Hers Pulls Copycat Wegovy Pill After FDA Threats
• Negative Sentiment: Multiple news reports and coverage highlight steep stock drops and investor panic after the GLP‑1 rollout backfired, amplifying volatility and prompting margin/valuation repricing. Hims & Hers Stock Plunges 24%. Its Weight-Loss Drug Strategy Backfired.
• Negative Sentiment: Analyst downgrades / lower expectations: Bank of America, Citi, TD Cowen and others have cut forecasts or signaled lower price targets amid rising legal/regulatory uncertainty. Bank of America Has Lowered Expectations for Hims & Hers Health (NYSE:HIMS) Stock Price
• Negative Sentiment: Industry/legal coverage: extensive media coverage (Forbes, LA Times, Healthline) and further legal filings keep scrutiny high and could prolong investor uncertainty and share pressure. Why Hims Stock Slid 40 In A Month?

Hedge Funds Weigh In On Hims & Hers Health

A number of institutional investors and hedge funds have recently added to or reduced their stakes in HIMS. VIRGINIA RETIREMENT SYSTEMS ET Al boosted its holdings in Hims & Hers Health by 0.8% in the 3rd quarter. VIRGINIA RETIREMENT SYSTEMS ET Al now owns 25,600 shares of the company’s stock worth $1,452,000 after buying an additional 200 shares during the period. GAMMA Investing LLC lifted its position in shares of Hims & Hers Health by 6.1% during the third quarter. GAMMA Investing LLC now owns 4,098 shares of the company’s stock worth $232,000 after acquiring an additional 236 shares in the last quarter. Concurrent Investment Advisors LLC boosted its holdings in shares of Hims & Hers Health by 1.8% in the third quarter. Concurrent Investment Advisors LLC now owns 13,984 shares of the company’s stock worth $793,000 after acquiring an additional 252 shares during the period. Smartleaf Asset Management LLC grew its position in shares of Hims & Hers Health by 44.7% in the third quarter. Smartleaf Asset Management LLC now owns 916 shares of the company’s stock valued at $54,000 after purchasing an additional 283 shares in the last quarter. Finally, Bessemer Group Inc. raised its stake in shares of Hims & Hers Health by 105.8% during the 2nd quarter. Bessemer Group Inc. now owns 607 shares of the company’s stock valued at $30,000 after purchasing an additional 312 shares during the period. Institutional investors own 63.52% of the company’s stock.

Hims & Hers Health Price Performance

The business has a fifty day moving average of $31.81 and a 200-day moving average of $42.59. The firm has a market cap of $3.79 billion, a PE ratio of 30.84, a PEG ratio of 3.02 and a beta of 2.43. The company has a current ratio of 1.88, a quick ratio of 1.64 and a debt-to-equity ratio of 1.67.

Hims & Hers Health announced that its Board of Directors has initiated a share repurchase program on Monday, November 17th that permits the company to repurchase $250.00 million in outstanding shares. This repurchase authorization permits the company to purchase up to 3% of its shares through open market purchases. Shares repurchase programs are usually an indication that the company’s management believes its stock is undervalued.

Hims & Hers Health Company Profile

Hims & Hers Health, Inc is a telehealth platform providing direct-to-consumer personal care products and virtual medical services in the United States. Operating under the Hims & Hers brand, the company offers an integrated digital experience that connects users with licensed healthcare providers, enabling online consultations and prescriptions for a range of conditions. Its telemedicine infrastructure supports both prescription medications and over-the-counter products, with home delivery to patients’ doorsteps.

The company’s product portfolio addresses key areas of men’s and women’s health, including hair loss treatments, sexual wellness therapies, skincare regimens and mental health support.